WFRF:(Jensen Jane)
Sökning: WFRF:(Jensen Jane) > Safety and efficacy...
- 33 av 47
- Föregående post
- Nästa post
- Till träfflistan
Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study.
-
- Prescott, Eva (författare)
- Univ Copenhagen, Bispebjerg Hosp, Dept Cardiol, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark.,University of Copenhagen
-
- Angerås, Oskar, 1976 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine,Univ Gothenburg, Sahlgrenska Acad, Dept Mol & Clin Med, Gothenburg, Sweden.;Sahlgrens Univ Hosp, Dept Cardiol, Gothenburg, Sweden.,Sahlgrenska University Hospital
-
- Erlinge, David (författare)
- Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular Cardiology,Lund University Research Groups,Skåne University Hospital
- visa fler...
- visa färre...
- Univ Copenhagen, Bispebjerg Hosp, Dept Cardiol, Bispebjerg Bakke 23, DK-2400 Copenhagen, Denmark University of Copenhagen (creator_code:org_t)
- Elsevier BV, 2022
- 2022
- Engelska.
- Ingår i: International journal of cardiology. - : Elsevier BV. - 1874-1754 .- 0167-5273. ; 365, s. 34-40
- Tidskriftsartikel (refereegranskat)
Abstract
Ämnesord
Stäng
- Leukotrienes are pro-inflammatory vasoactive lipid mediators implicated in the pathophysiology of atherosclerotic cardiovascular disease. We studied the effect of the 5-lipoxygenase-activating protein inhibitor AZD5718 on leukotriene biosynthesis and coronary microvascular function in a single-blind, phase 2a study.Patients 7-28days after myocardial infarction (±ST elevation), with <50% left anterior descending coronary artery stenosis and Thrombolysis in Myocardial Infarction flow grade≥2 after percutaneous coronary intervention, were randomized 2:1:2 to once-daily AZD5718 200mg or 50mg, or placebo, in 4- and 12-week cohorts. Change in urine leukotriene E4 (uLTE4) was the primary endpoint, and coronary flow velocity reserve (CFVR; via echocardiography) was the key secondary endpoint.Of 129 randomized patients, 128 received treatment (200mg, n=52; 50mg, n=25; placebo, n=51). Statistically significant reductions in uLTE4 levels of >80% were observed in both AZD5718 groups versus the placebo group at 4 and 12weeks. No significant changes in CFVR were observed for AZD5718 versus placebo. Adverse events (AEs) occurred in 12/18, 3/6 and 6/13 patients receiving 200mg, 50mg and placebo, respectively, in the 4-week cohort, and in 27/34, 14/19 and 24/38 patients, respectively, in the 12-week cohort. Serious AEs in seven patients receiving AZD5718 and four receiving placebo were not treatment-related, and there were no deaths.In patients with recent myocardial infarction, AZD5718 was well tolerated, and leukotriene biosynthesis was dose-dependently inhibited. No significant changes in CFVR were detected.gov identifier: NCT03317002.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- 5-Lipoxygenase-Activating Protein Inhibitors
- therapeutic use
- 5-Lipoxygenase-Activating Proteins
- Coronary Stenosis
- drug therapy
- Humans
- Myocardial Infarction
- drug therapy
- Pyrazoles
- Single-Blind Method
- Treatment Outcome
- 5-Lipoxygenase activating protein
- 5-Lipoxygenase activating protein
- Cardiovascular disease
- Leukotriene
- Randomized clinical trial
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
- International journal of cardiology (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
- 33 av 47
- Föregående post
- Nästa post
- Till träfflistan
Hitta mer i SwePub
- Av författaren/redakt...
- Prescott, Eva
- Angerås, Oskar, ...
- Erlinge, David
- Grove, Erik L
- Hedman, Marja
- Jensen, Lisette ...
- visa fler...
- Pernow, John
- Saraste, Antti
- Åkerblom, Axel A ...
- Svedlund, Sara
- Rudvik, Anna
- Knöchel, Jane
- Lindstedt, Eva-L ...
- Garkaviy, Pavlo
- Gan, Li-Ming, 19 ...
- Gabrielsen, Ande ...
- visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
- MEDICIN OCH HÄLS ...
- och Klinisk medicin
- och Kardiologi
- Artiklar i publikationen
- International jo ...
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
